Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2


Spinal and bulbar muscular atrophy (SBMA) is an inherited neurodegenerative disorder caused by the expansion of the polyglutamine (polyQ) tract of the androgen receptor (AR-polyQ)1,2. Characteristics of SBMA include proximal muscular atrophy, weakness, contraction fasciculation and bulbar involvement3. MicroRNAs (miRNAs) are a diverse class of highly conserved small RNA molecules that function as crucial regulators of gene expression in animals and plants4. Recent functional studies have shown the potent activity of specific miRNAs as disease modifiers both in vitro and in vivo5,6,7,8. Thus, potential therapeutic approaches that target the miRNA processing pathway have recently attracted attention9,10. Here we describe a novel therapeutic approach using the adeno-associated virus (AAV) vector–mediated delivery of a specific miRNA for SBMA. We found that miR-196a enhanced the decay of the AR mRNA by silencing CUGBP, Elav-like family member 2 (CELF2). CELF2 directly acted on AR mRNA and enhanced the stability of AR mRNA. Furthermore, we found that the early intervention of miR-196a delivered by an AAV vector ameliorated the SBMA phenotypes in a mouse model. Our results establish the proof of principle that disease-specific miRNA delivery could be useful in neurodegenerative diseases.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Treatment with miR-196a and miR-196b and the knockdown of CELF2 expression decreased the expression of AR mRNA and protein in HEK293T cells.
Figure 2: CELF2 recognizes the sequence CUGCUGCUG in exon 1 of the AR mRNA and increases the stability of the AR mRNA.
Figure 3: The effects of miR-196a on the phenotype of male AR-97Q mice.
Figure 4: The effects of miR-196a on mutant AR expression in male AR-97Q mice and patients with SBMA.

Accession codes


NCBI Reference Sequence


  1. 1

    La Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E. & Fischbeck, K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77–79 (1991).

    CAS  Article  Google Scholar 

  2. 2

    Kennedy, W.R., Alter, M. & Sung, J.H. Progressive proximal spinal and bulbar muscular atrophy of late onset: a sex-linked recessive trait. Neurology 50, 583–593 (1998).

    Article  Google Scholar 

  3. 3

    Sobue, G. et al. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 112, 209–232 (1989).

    Article  Google Scholar 

  4. 4

    Kim, V.N., Han, J. & Siomi, M.C. Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol. 10, 126–139 (2009).

    CAS  Article  Google Scholar 

  5. 5

    Kim, J. et al. A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317, 1220–1224 (2007).

    CAS  Article  Google Scholar 

  6. 6

    Karres, J.S., Hilgers, V., Carrera, I., Treisman, J. & Cohen, S.M. The conserved microRNA miR-8 tunes atrophin levels to prevent neurodegeneration in Drosophila. Cell 131, 136–145 (2007).

    CAS  Article  Google Scholar 

  7. 7

    Lee, Y. et al. miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis. Nat. Neurosci. 11, 1137–1139 (2008).

    CAS  Article  Google Scholar 

  8. 8

    Williams, A.H. et al. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 326, 1549–1554 (2009).

    CAS  Article  Google Scholar 

  9. 9

    Roshan, R., Ghosh, T., Scaria, V. & Pillai, B. MicroRNAs: novel therapeutic targets in neurodegenerative diseases. Drug Discov. Today 14, 1123–1129 (2009).

    CAS  Article  Google Scholar 

  10. 10

    Boudreau, R.L., Rodríguez-Lebrón, E. & Davidson, B.L. RNAi medicine for the brain: progresses and challenges. Hum. Mol. Genet. 20, R21–R27 (2011).

    CAS  Article  Google Scholar 

  11. 11

    Katsuno, M. et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35, 843–854 (2002).

    CAS  Article  Google Scholar 

  12. 12

    Katsuno, M. et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat. Med. 9, 768–773 (2003).

    CAS  Article  Google Scholar 

  13. 13

    Adachi, H. et al. Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J. Neurosci. 23, 2203–2211 (2003).

    CAS  Article  Google Scholar 

  14. 14

    Waza, M. et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med. 11, 1088–1095 (2005).

    CAS  Article  Google Scholar 

  15. 15

    Tokui, K. et al. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum. Mol. Genet. 18, 898–910 (2009).

    CAS  Article  Google Scholar 

  16. 16

    Eacker, S.M., Dawson, T.M. & Dawson, V.L. Understanding microRNAs in neurodegeneration. Nat. Rev. Neurosci. 10, 837–841 (2009).

    CAS  Article  Google Scholar 

  17. 17

    Bilen, J., Liu, N., Burnett, B.G., Pittman, R.N. & Bonini, N.M. MicroRNA pathways modulate polyglutamine-induced neurodegeneration. Mol. Cell 24, 157–163 (2006).

    CAS  Article  Google Scholar 

  18. 18

    Schaefer, A. et al. Cerebellar neurodegeneration in the absence of microRNAs. J. Exp. Med. 204, 1553–1558 (2007).

    CAS  Article  Google Scholar 

  19. 19

    Kaspar, B.K. et al. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301, 839–842 (2003).

    CAS  Article  Google Scholar 

  20. 20

    Towne, C. et al. Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther. 17, 141–146 (2010).

    CAS  Article  Google Scholar 

  21. 21

    Dominguez, E. et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum. Mol. Genet. 20, 681–693 (2011).

    CAS  Article  Google Scholar 

  22. 22

    Fu, H., Dirosario, J., Killedar, S., Zaraspe, K. & McCarty, D.M. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol. Ther. 19, 1025–1033 (2011).

    CAS  Article  Google Scholar 

  23. 23

    Petrs-Silva, H. et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol. Ther. 19, 293–301 (2011).

    CAS  Article  Google Scholar 

  24. 24

    Hui, A.B. et al. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab. Invest. 89, 597–606 (2009).

    CAS  Article  Google Scholar 

  25. 25

    Maru, D.M. et al. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am. J. Pathol. 174, 1940–1948 (2009).

    CAS  Article  Google Scholar 

  26. 26

    Yekta, S., Shih, I.H. & Bartel, D.P. MicroRNA-directed cleavage of HOXB8 mRNA. Science 304, 594–596 (2004).

    CAS  Article  Google Scholar 

  27. 27

    Hornstein, E. et al. The microRNA miR-196 acts upstream of Hoxb8 and Shh in limb development. Nature 438, 671–674 (2005).

    CAS  Article  Google Scholar 

  28. 28

    Pedersen, I.M. et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449, 919–922 (2007).

    CAS  Article  Google Scholar 

  29. 29

    Dhaenens, C.M. et al. Mis-splicing of Tau exon 10 in myotonic dystrophy type 1 is reproduced by overexpression of CELF2 but not by MBNL1 silencing. Biochim. Biophys. Acta 1812, 732–742 (2011).

    CAS  Article  Google Scholar 

  30. 30

    Natarajan, G. et al. CUGBP2 downregulation by prostaglandin E2 protects colon cancer cells from radiation-induced mitotic catastrophe. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G1235–G1244 (2008).

    CAS  Article  Google Scholar 

  31. 31

    Subramaniam, D. et al. RNA binding protein CUGBP2/CELF2 mediates curcumin-induced mitotic catastrophe of pancreatic cancer cells. PLoS ONE 6, e16958 (2011).

    CAS  Article  Google Scholar 

  32. 32

    Kobayashi, Y. et al. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J. Biol. Chem. 275, 8772–8778 (2000).

    CAS  Article  Google Scholar 

  33. 33

    Katsuno, M. et al. Disrupted transforming growth factor-β signaling in spinal and bulbar muscular atrophy. J. Neurosci. 30, 5702–5712 (2010).

    CAS  Article  Google Scholar 

  34. 34

    Gao, G. et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381–6388 (2004).

    CAS  Article  Google Scholar 

  35. 35

    Li, X.G. et al. Viral-mediated temporally controlled dopamine production in a rat model of Parkinson disease. Mol. Ther. 13, 160–166 (2006).

    CAS  Article  Google Scholar 

Download references


We are grateful to T. Cooper (Department of Pathology and Immunology, Baylor College of Medicine) for kindly providing the plasmid expressing human CELF2. We also thank N. Takino, H. Miyauchi and K. Ayabe (Division of Neurology, Department of Medicine, Jichi Medical University) for their help with the production of the AAV vectors and Y. Kondo and K. Shinjo (Division of Molecular Oncology, Aichi Cancer Center Research Institute) for expert technical support and helpful discussions. This work was supported by grants from the Ministry of Health, Labor and Welfare; grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; a Center-of-Excellence (COE) grant; a Grant-in-Aid for Scientific Research on Innovated Areas “Foundations of Synapse and Neurocircuit Pathology”; and the Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology Agency (JST).

Author information




Project planning was done by Y.M., H.A., M.K., F.T., S. Muramatsu and G.S.; experimental work was done by Y.M., H.A., M.K., M.M., Y.-M.J., Z.H., H.D., S. Matsumoto, N.K., M.I., G.T. and S. Muramatsu; data analysis was done by Y.M., H.A., M.K., F.T., S. Muramatsu and G.S.; the manuscript was written by Y.M., H.A., M.K., F.T., S. Muramatsu and G.S.

Corresponding author

Correspondence to Gen Sobue.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Note and Supplementary Figures 1–10 (PDF 7641 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Miyazaki, Y., Adachi, H., Katsuno, M. et al. Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nat Med 18, 1136–1141 (2012).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing